Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interaction of Tegoprazan or RAPA113 with Clopidogrel in Healthy Males
NCT04171687Phase 1Completed
- Sponsor
- HK inno.N Corporation
- Start
- Oct 2019
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tegoprazan and RAPA113 in gastroesophageal reflux disease (GERD) (3 arms), sponsored by HK inno.N Corporation. Primary endpoint: Change in P2Y12 Reaction Unit (PRU) from baseline. Started Oct 2019; status: completed.
02
Drugs
tegoprazanRAPA113
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT04171687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04171687.